CAM
KROS icon

Cresset Asset Management’s Keros Therapeutics KROS Stock Holding History

Cresset Asset Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4,938
Closed -$287K – 2003
2024
Q3 		$287K Buy
4,938
+37
+0.8% +$1.83K ﹤0.01% 1819
2024
Q2 		$224K Sell
4,901
-26
-0.5% -$1.4K ﹤0.01% 1850
2024
Q1 		$326K Sell
4,927
-2,249
-31% -$133K ﹤0.01% 1538
2023
Q4 		$285K Sell
7,176
-506
-7% -$15.9K ﹤0.01% 1512
2023
Q3 		$245K Hold
7,682
– – ﹤0.01% 1531
2023
Q2 		$309K Buy
+7,682
New +$337K ﹤0.01% 1509

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Cresset Asset Management's KROS Position: Q4 2024 in Review

Cresset Asset Management sold out of Keros Therapeutics (KROS) in Q4 2024, closing a stake of 4,938 shares — an estimated $287K sold.

Cresset Asset Management first reported a position in KROS in Q2 2023 and held it in 6 quarters. The position peaked at $326K in Q1 2024. 161 funds tracked by Wall St. Rank hold KROS as of Q4 2024.

  • Cresset Asset Management reported no remaining Keros Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Cresset Asset Management sold 4,938 Keros Therapeutics shares in Q4 2024, an estimated $287K.
  • Cresset Asset Management first reported a position in Keros Therapeutics in Q2 2023 and held it in 6 quarters.
  • Cresset Asset Management's Keros Therapeutics position peaked at $326K in Q1 2024.
  • 161 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2024.

Based on Cresset Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.